Wanbury (BSE:524212) - Stock Price, News & Analysis

524212 Stock Overview

Wanbury Limited produziert und verkauft Formulierungen und aktive pharmazeutische Wirkstoffe (API) in Indien.

524212 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	0/6
Dividends	0/6

Rewards

Das Kurs-Gewinn-Verhältnis (20.3x) liegt unter dem Indian Markt (31x)

Risk Analysis

Negatives Eigenkapital

Zinszahlungen sind nicht ausreichend durch Erträge gedeckt

Hat keine nennenswerte Marktkapitalisierung (₹4B)

Die Gewinnspannen (1.8%) sind niedriger als im Vorjahr (15%)

Wanbury Limited Competitors

ZIM Laboratories

BSE:541400

₹4.7b

Medicamen Biotech

BSE:531146

₹5.4b

Accent Microcell

NSEI:ACCENTMIC

₹5.7b

Vikram Thermo (India)

BSE:530477

₹4.7b

Price History & Performance

Summary of all time highs, changes and price drops for Wanbury
Historical stock prices
Current Share Price	₹161.05
52 Week High	₹177.40
52 Week Low	₹34.06
Beta	0.41
1 Month Change	2.45%
3 Month Change	24.56%
1 Year Change	295.41%
3 Year Change	67.50%
5 Year Change	571.04%
Change since IPO	-13.58%

Recent updates

Shareholder Returns

	524212	IN Pharmaceuticals	IN Market
7D	10.4%	1.9%	3.6%
1Y	295.4%	63.3%	48.8%

Rendite im Vergleich zur Industrie: 524212 übertraf die Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 65.4 erzielte.

Rendite vs. Markt: 524212 übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 44.7 erzielte.

Price Volatility

Is 524212's price volatile compared to industry and market?
524212 volatility
524212 Average Weekly Movement	6.6%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.8%
10% most volatile stocks in IN Market	10.4%
10% least volatile stocks in IN Market	4.2%

Stabiler Aktienkurs: 524212 hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: 524212Die wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

About the Company

Founded	Employees	CEO	Website
1988	1,582	Mohan Rayana	https://www.wanbury.com

Wanbury Limited produziert und verkauft Formulierungen und aktive pharmazeutische Inhaltsstoffe (API) in Indien. Das Unternehmen bietet Formulierungen für die Gynäkologie, Orthopädie, Heamatinika, Antidiabetika, Nutrazeutika, Magen-Darm-Präparate, Schlaganfallchirurgie, Antibiotika, Husten- und Erkältungspräparate, entzündungshemmende Mittel, Analgetika und Allgemeinmediziner an. Darüber hinaus bietet das Unternehmen API-Produkte für die Therapiebereiche Antidiabetika, Analgetika, Antidepressiva, Antihistaminika, Entzündungshemmer, Arthritishemmer, Antithrombotika, Antiepileptika und Antihypertonika an.

Wanbury Limited Fundamentals Summary

How do Wanbury's earnings and revenue compare to its market cap?
524212 fundamental statistics
Market cap	₹5.34b
Earnings (TTM)	₹233.39m
Revenue (TTM)	₹5.69b

22.6x

P/E Ratio

0.9x

P/S Ratio

Is 524212 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524212 income statement (TTM)
Revenue	₹5.69b
Cost of Revenue	₹3.12b
Gross Profit	₹2.57b
Other Expenses	₹2.34b
Earnings	₹233.39m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	7.13
Gross Margin	45.13%
Net Profit Margin	4.10%
Debt/Equity Ratio	-509.4%

How did 524212 perform over the long term?

See historical performance and comparison

524212 Stock Overview

Rewards

Risk Analysis

Wanbury Limited Competitors

BSE:541400

₹4.7b

BSE:531146

₹5.4b

NSEI:ACCENTMIC

₹5.7b

BSE:530477

₹4.7b

Price History & Performance

Recent News & Updates

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 18%

Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director

Third quarter 2024 earnings released: EPS: ₹3.14 (vs ₹1.00 loss in 3Q 2023)

Wanbury Limited to Report Q3, 2024 Results on Jan 24, 2024

Wanbury Limited Approves Appointment of Pravin Dilip Pawar as the Non-Executive Independent Director

Recent updates

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 18%

Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director

Third quarter 2024 earnings released: EPS: ₹3.14 (vs ₹1.00 loss in 3Q 2023)

Wanbury Limited to Report Q3, 2024 Results on Jan 24, 2024

Wanbury Limited Approves Appointment of Pravin Dilip Pawar as the Non-Executive Independent Director

Second quarter 2024 earnings released: EPS: ₹2.25 (vs ₹0.27 loss in 2Q 2023)

Wanbury Limited to Report Q2, 2024 Results on Oct 20, 2023

New major risk - Negative shareholders equity

Wanbury Limited, Annual General Meeting, Sep 27, 2023

Wanbury Limited Appoints Mohan Kumar Rayana as Whole Time Director

First quarter 2024 earnings released: EPS: ₹1.43 (vs ₹2.22 loss in 1Q 2023)

Wanbury Limited to Report Q1, 2024 Results on Aug 11, 2023

Full year 2023 earnings released: ₹3.18 loss per share (vs ₹25.29 profit in FY 2022)

Wanbury Limited to Report Q4, 2023 Results on Jun 26, 2023

Investor sentiment improves as stock rises 20%

Wanbury Limited to Report Q4, 2023 Results on May 30, 2023

Investor sentiment improves as stock rises 27%

Third quarter 2023 earnings released: ₹1.00 loss per share (vs ₹0.12 profit in 3Q 2022)

Wanbury Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: ₹0.27 loss per share (vs ₹0.17 loss in 2Q 2022)

Investor sentiment deteriorated over the past week

Wanbury Limited to Report Q2, 2023 Results on Nov 11, 2022

Investor sentiment improved over the past week

Wanbury Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: ₹2.22 loss per share (vs ₹0.28 loss in 1Q 2022)

Investor sentiment improved over the past week

Wanbury Limited to Report Q1, 2023 Results on Aug 10, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹25.29 (vs ₹5.04 loss in FY 2021)

Wanbury Limited to Report Q4, 2022 Results on Jun 22, 2022

Wanbury Limited announced that it expects to receive INR 143.0625 million in funding from Expert Chemicals (India) Pvt. Ltd.

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Wanbury Limited to Report Q3, 2022 Results on Feb 08, 2022

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

First quarter 2022 earnings released: ₹0.28 loss per share (vs ₹4.47 loss in 1Q 2021)

Full year 2021 earnings released: ₹5.04 loss per share (vs ₹26.90 profit in FY 2020)

Investor sentiment improved over the past week

Wanbury Limited announced that it has received INR 494.999765 million in funding from Bakliwal Fincom Pvt Ltd, Radhakrishna Ramnarain Private Limited, Niche Financial Services Pvt. Ltd, Vidyut Merchandise Pvt Ltd, Dalal & Broacha Stock Broking Pvt Ltd., Asset Management Arm and other investors

Investor sentiment improved over the past week

New 90-day high: ₹94.70

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹2.36 (vs ₹0.90 loss in 3Q 2020)

Wanbury Limited Approves Board Appointments

Wanbury Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹60.60

Investor sentiment improved over the past week

New 90-day high: ₹43.85

New 90-day high: ₹38.10

Wanbury Limited to Report Q2, 2021 Results on Nov 12, 2020

Wanbury Limited to Report Q1, 2021 Results on Sep 11, 2020

New 90-day high - ₹33.95

Wanbury Limited to Report Q4, 2020 Final Results on Jul 22, 2020

Shareholder Returns

Price Volatility

About the Company

Wanbury Limited Fundamentals Summary

22.6x

0.9x